PolyBio
PolyBio Research Foundation is a 501(c)(3) nonprofit founded in 2021 that funds and coordinates research on infection-driven chronic diseases, including Long COVID, ME/CFS, and chronic Lyme, across leading U.S. academic institutions and has disbursed over $50M since inception.
- Company typePrivate
- Founded2021
- HeadquartersMedford, United States
- Headcount—
- GTM typeB2B
- OfferingServices
What PolyBio does
PolyBio Research Foundation is a 501(c)(3) nonprofit research foundation founded in 2021 and headquartered in Medford, Massachusetts. It advances research into how viral, bacterial, and parasite infections contribute to chronic disease and aging, with primary focus on Long COVID, Chronic Lyme Disease, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), and other post-infectious conditions. The foundation operates a consortium-style model, coordinating 54+ active research projects and 6 clinical trials across leading U.S. academic and research institutions including Harvard, Stanford, Yale, Mount Sinai, UCSF, the University of Pennsylvania, the J. Craig Venter Institute, and Arizona State University. PolyBio-affiliated work has produced publications in high-impact journals such as Nature and Cell.
The foundation's core technical surface spans diagnostic development (including the VIPER program with $1.35M deployed to UCSF and the MENSA program), tissue and biomarker analysis, neuroimaging, microbiome research, and clinical trials such as a Balvi Fund-supported rapamycin study and HIV antiviral investigations. Its underlying platform is best characterized as a coordinated research network rather than a single technology stack; the foundation provides funding, shared protocols, and translational coordination, and is now extending into commercialization via a newly launched Commercialization Advisory Network. Underlying assets include multi-institutional tissue repositories and biomarker datasets that are difficult to replicate outside this consortium structure.
As a nonprofit, PolyBio does not generate commercial revenue through product sales; its income is donation- and grant-based. Since inception, the foundation has disbursed more than $50 million in research funding, with anchor donors including the Balvi Fund (associated with Vitalik Buterin) and the Steve & Alexandra Cohen Foundation. Its customers, in a functional sense, are patient communities affected by infection-associated chronic diseases, while its counterparties are academic research partners, clinical trial sponsors, and major philanthropic funders. The Commercialization Advisory Network represents a deliberate shift toward capturing downstream value from research outputs rather than remaining a pure grant-making entity.
PolyBio firmographics
Firmographics- Name
- PolyBio
- Legal name
- PolyBio Research Foundation
- Website
- https://polybio.org
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Short description
- PolyBio Research Foundation is a 501(c)(3) nonprofit founded in 2021 that funds and coordinates research on infection-driven chronic diseases, including Long COVID, ME/CFS, and chronic Lyme, across leading U.S. academic institutions and has disbursed over $50M since inception.
- Ownership category
- akta.pro rank
PolyBio industry classification
Industry- Product category
- Nonprofit Biomedical Research
- NAICS
- Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS) (BPAGACAA)
- akta.pro secondary industries
- Global Health Research, Clinical Trials & Product Development Partnerships (PDPs) (HLAJAOAM), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Biomedical Sciences & Medical Research Institutes (University-Based) (EDAHAGAI)
Keywords
Where PolyBio is headquartered
LocationHeadquarters
- HQ city
- Medford
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
PolyBio business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Revenue model
- Philanthropic Donations: PolyBio is a 501(c)(3) nonprofit organization that receives funding through donations from individuals, foundations, and partners. The website prominently features a 'Donate' button and mentions donor partnerships as key to empowering their mission to fight on behalf of millions of ME/CFS and chronic illness patients.
- Research Grants and Funding: Funding from organizations such as the Balvi Fund (Vitalik Buterin's fund) to expand clinical trials like the Long COVID rapamycin trial, and initial $1.35 million deployed to UCSF for VIPER program.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels7 records
PolyBio product offering
Product offeringCore offering
PolyBio Research Foundation is a 501(c)(3) nonprofit research foundation that coordinates collaborative research on how viral, bacterial, and parasite infections drive chronic disease and aging. It funds and manages the Long COVID Cure Initiative, the VIPER diagnostic validation program, the Long COVID Research Consortium, multiple clinical trials (including low-dose rapamycin and repurposed HIV antivirals), and the MENSA diagnostic testing platform for Long COVID, ME/CFS, and Chronic Lyme Disease.
Product overview
PolyBio Research Foundation is a 501(c)(3) research organization advancing research on how viral, bacterial, and parasite infections drive chronic disease and aging. The organization's primary offerings include the Long COVID Cure Initiative (LCCI), a four-step translational research program; VIPER, the diagnostic validation program within LCCI; the Long COVID Research Consortium connecting scientists from major institutions; and the Commercialization Advisory Network. PolyBio also conducts multiple clinical trials including low-dose rapamycin and repurposed HIV antivirals, and supports the MENSA diagnostic testing platform for viral immune response detection.
Differentiator
Problem solved
Functional benefit
Products and services
- Long COVID Cure Initiative (LCCI) A four-step translational research program designed to move biological discovery into real-world treatments for Long COVID, including precise diagnosis, personalized care linking patient biology to therapies, and acceleration of cures through science-industry-philanthropy collaboration. Directed at scientists, clinicians, and patients affected by Long COVID.
- VIPER (Viral Immunopathogenesis and Persistence Repeat Donor Cohort) First phase of the Long COVID Cure Initiative: a large-scale diagnostic validation program that conducts head-to-head evaluation of leading diagnostic approaches to determine which tests most accurately detect core disease mechanisms of Long COVID. Designed for researchers, clinicians, and diagnostic developers working on Long COVID.
- Long COVID Research Consortium Scientific collaboration involving scientists and clinicians from Harvard Medical School, Stanford University, University of Pennsylvania, Icahn School of Medicine at Mount Sinai, Yale University, UCSF, and J. Craig Venter Institute, designed to rapidly and comprehensively study Long COVID. For researchers studying infection-associated chronic diseases.
- Commercialization Advisory Network Initiative designed to accelerate the translation of Long COVID and related chronic disease discoveries into clinical diagnostics and targeted treatments through industry partnerships and commercialization expertise. For diagnostics developers, therapeutics companies, and commercialization partners.
- Long COVID Low-Dose Rapamycin Clinical Trial Double-blinded randomized controlled pilot clinical trial at Mount Sinai's Cohen Center for Recovery from Complex Chronic Illness to determine if low-dose rapamycin can improve symptoms in patients with Long COVID. For Long COVID patients and clinical investigators.
- Repurposed HIV Antivirals Clinical Trial (Truvada & Maraviroc) Clinical trial testing if two repurposed HIV antivirals (Truvada and Maraviroc) can reduce symptom burden in patients with Long COVID over 90 days, with analyses of infectious, immune, and metabolic biomarkers. For Long COVID patients and clinical investigators.
- MENSA Virus Immune Snapshot Testing A diagnostic method that captures virus-specific immune cell responses secreted exclusively from circulating human plasmablasts, providing an immune snapshot to clarify if a patient's immune system is responding to persistent viral infection. For clinicians and researchers studying chronic viral infections.
Quantifiable outcome
- $50M+ in research fund disbursement
- +4 more outcomes
Companies that use PolyBio
Customer profileSegments3 records
Ideal customer profiles3 records
PolyBio technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
PolyBio partnerships and signals
Strategic signalPartnerships
16 partnerships are on record, tiered core and secondary.
- University of California San Francisco (UCSF)coreInitial $1.35 million deployed to UCSF to initiate the VIPER (Viral Immunopathogenesis and Persistence Repeat Donor Cohort) program, the first large-scale diagnostic validation program for Long COVID.
- Harvard Medical SchoolcoreHarvard Medical School is part of the Long COVID Research Consortium, contributing scientists and clinicians to collaborative research projects studying infection-associated chronic diseases.
- Stanford UniversitycoreStanford University is part of the Long COVID Research Consortium, contributing researchers to collaborative studies on Long COVID and related conditions.
- Yale UniversitycoreYale University is part of the Long COVID Research Consortium. Dr. Akiko Iwasaki's lab at Yale is studying SARS-CoV-2 and Long COVID biological mechanisms, and is involved in the rapamycin clinical trial.
- Icahn School of Medicine at Mount SinaicoreMount Sinai is part of the Long COVID Research Consortium. The Cohen Center for Recovery from Complex Chronic Illness at Mount Sinai is a key clinical trial site. Dr. David Putrino serves as Director of Rehabilitation Innovation.
- University of California San Francisco (UCSF)coreUCSF is part of the Long COVID Research Consortium and received initial $1.35 million funding for the VIPER diagnostic validation program. Dr. Tim Henrich leads research on viral persistence and ImmunoPET-CT imaging.
- University of PennsylvaniacoreUniversity of Pennsylvania is part of the Long COVID Research Consortium. Dr. John Wherry's lab studies T cell responses and exhaustion in Long COVID.
- J. Craig Venter InstitutecoreJ. Craig Venter Institute is part of the Long COVID Research Consortium. Dr. Marcelo Freire's lab at JCVI studies oral pathogens and chronic disease.
- Mount Sinai Center for Post-COVID CarecoreMount Sinai's Center for Post-COVID Care, launched in May 2020 as the first major multidisciplinary Long COVID treatment and research center in the USA, collaborates on clinical trials and research projects.
- Feinstein Institutes for Medical ResearchsecondaryDr. Kevin Tracey, president and CEO of Feinstein Institutes, is interviewed by PolyBio and is an expert on vagus nerve signaling and bioelectronic medicine relevant to Long COVID research.
- Tulane University National Primate Research CentersecondaryDr. Monica Embers' lab at Tulane studies Borrelia burgdorferi (Lyme disease) and is interviewed by PolyBio for Lyme and tissue research collaboration.
- Northeastern UniversitysecondaryDr. Kim Lewis, University Distinguished Professor at Northeastern and Director of the Antimicrobial Discovery Center, collaborates on Lyme disease persister cell research.
- Arizona State University Banner Neurodegenerative Disease Research CentercoreDr. Benjamin Readhead's team at ASU is validating a cytomegalovirus-based biomarker for Alzheimer's disease and studying infectious contributions to neurodegenerative diseases.
- University of Massachusetts Medical SchoolsecondaryDr. Liisa Selin's lab studies T cell exhaustion and viral activity in ME/CFS, collaborating on understanding immune responses in chronic illness.
- University of Pennsylvania School of MedicinesecondaryDr. Sara Cherry's lab uses tissue models and screening technologies to identify antiviral strategies for SARS-CoV-2 persistence research.
- Commercialization Advisory NetworkcoreA new initiative designed to accelerate the translation of Long COVID and related chronic disease discoveries into clinical diagnostics and targeted treatments.
Scale indicators5 records
Recent moves7 records
Expansion highlights5 records
PolyBio competitors and assessment
Company assessmentDirect peers
- Patient-Led Research Collaborative: Patient-led research collaborative focused on Long COVID and chronic illness, producing peer-reviewed publications. Highly comparable grassroots, patient-centered research model targeting similar conditions.
- J. Craig Venter Institute: Genomics and infectious disease research organization that is both a PolyBio consortium partner and a peer in microbiome/metagenomic chronic disease research. Direct overlap on pathogen-driven disease research.
- Open Medicine Foundation: 501(c)(3) nonprofit research foundation focused on ME/CFS, Long COVID, and related infection-associated chronic diseases. Highly comparable mission, funding model, and disease focus as PolyBio.
- Solve M.E. Long-standing nonprofit organization dedicated to ME/CFS and Long COVID research, advocacy, and patient support. Overlapping disease focus, philanthropic funding model, and research consortium structure.
- Cohen Center for Recovery from Complex Chronic Illness (Mount Sinai): Clinical and research center at Mount Sinai focused on Long COVID and complex chronic illness; receives PolyBio funding and conducts clinical trials in the same disease space.
Broad incumbents
- Howard Hughes Medical Institute: Large biomedical research organization funding investigator-driven science across universities. Comparable model of distributing research funding to top-tier academic labs to drive discovery.
- Scripps Research Translational Institute: Major biomedical research institute conducting translational research on chronic and infectious diseases. Overlapping scientific scope on pathogen persistence and microbiome-driven disease.
- NIH RECOVER Initiative: Federal research initiative with >$1B funding dedicated to studying Long COVID. Operates in the same disease area with vastly greater resources; both share the goal of understanding post-viral chronic illness.
- Chan Zuckerberg Initiative (CZI Biohub): Major philanthropic initiative funding biomedical research, including infectious disease and inflammation. Overlapping mission in advancing disease research via academic partnerships and large-scale funding.
Emerging players
- Innovative Genomics Institute: Research institute focused on CRISPR and genomic approaches to infectious disease and chronic illness. Comparable emerging research organization with overlap in pathogen-driven disease focus.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
PolyBio social profiles
Digital presencePolyBio financial estimates
Financial estimateRevenue estimate
Valuation estimate
PolyBio leadership team
Management profileNumber of profiles
Profiles16 records
PolyBio funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
PolyBio M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about PolyBio
What does PolyBio do?
PolyBio Research Foundation is a 501(c)(3) nonprofit research foundation that coordinates collaborative research on how viral, bacterial, and parasite infections drive chronic disease and aging. It funds and manages the Long COVID Cure Initiative, the VIPER diagnostic validation program, the Long COVID Research Consortium, multiple clinical trials (including low-dose rapamycin and repurposed HIV antivirals), and the MENSA diagnostic testing platform for Long COVID, ME/CFS, and Chronic Lyme Disease.
Is PolyBio a public or private company?
PolyBio is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was PolyBio founded?
PolyBio was founded in 2021.
Where is PolyBio based?
PolyBio is headquartered in Medford, United States, in the North America region.
How does PolyBio make money?
Two revenue lines are on record. Philanthropic Donations are the primary driver. The others are research Grants and Funding.
Who are PolyBio's main competitors?
Direct peers on record are Patient-Led Research Collaborative, J. Craig Venter Institute, Open Medicine Foundation, Solve M.E. and Cohen Center for Recovery from Complex Chronic Illness (Mount Sinai). Broad incumbents are Howard Hughes Medical Institute, Scripps Research Translational Institute, NIH RECOVER Initiative and Chan Zuckerberg Initiative (CZI Biohub). Innovative Genomics Institute is listed as an emerging player.
Does PolyBio have an API?
No public API is recorded for PolyBio.
What industry is PolyBio in?
PolyBio's product category is Nonprofit Biomedical Research. Its primary akta.pro industry code is BPAGACAA, Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS), with a secondary code of HLAJAOAM, Global Health Research, Clinical Trials & Product Development Partnerships (PDPs). Its NAICS code is 5417 and its SIC code is 8731.